Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
The company also announced the acquisition of Psyence Biomedical Ltd. (NASDAQ:PBM), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones.
Psyence生物醫藥有限公司（納斯達克：PBM），一家專注於開發基於天然致幻物質的解決方案來應對心理健康挑戰的生物技術公司，向股東發佈了更新，重點介紹了最近的重大進展和即將到來的里程碑。
The company has initiated a Phase IIb clinical trial in Australia to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in late 2025, with hopes to advance to a Phase III trial thereafter. Psyence also strengthened its clinical supply chain by partnering with Optimi Health (OTC:OPTHF) for GMP psilocybin extracts.
公司已在澳洲啓動了一項第IIb期臨床試驗，以評估輔助僞蓮盾治療對姑息護理中的調整障礙。預計將在2025年底公佈結果，希望隨後進行第III期試驗。Psyence還通過與Optimi Health（場外交易：OPTHF）合作，加強了其臨床供應鏈，提供GMP標準的僞蓮盾提取物。
In addition to its palliative care program, Psyence expanded its pipeline into Substance Use Disorders, specifically Alcohol Use Disorder (AUD), through an exclusive licensing agreement with Psylabs.
除了姑息護理項目外，Psyence還將其產品線擴展到物質使用障礙，具體是酒精使用障礙（AUD），通過與Psylabs的獨家許可協議。
The company also announced the acquisition of Clairvoyant, a synthetic psilocybin drug developer, enhancing Psyence's AUD development efforts with data expected in early 2025.
該公司還宣佈收購了Clairvoyant，一家合成僞蓮盾藥物開發公司，通過這一舉措增強了Psyence在AUD發展工作中的數據，預計將在2025年初公佈。
These initiatives position Psyence for two critical data readouts in 2025, potentially paving the way for commercial success. Psyence also emphasized its strengthened financial position to support these ventures. CEO Dr. Neil Maresky expressed optimism about Psyence's progress in developing psychedelic-based therapies for mental health.
這些舉措使Psyence爲2025年的兩個關鍵數據發佈做好準備，有望爲商業成功鋪平道路。Psyence還強調了其強大的財務狀況，以支持這些風險。首席執行官尼爾·馬雷斯基博士對Psyence在開發基於致幻物質的心理健康療法方面的進展表示樂觀。
Cover image made with AI
封面圖片由人工智能製作
譯文內容由第三人軟體翻譯。
